Epirus – Ranbaxy agreement for infliximab biosimilar in India & SEA

January 9, 2014 11:47 AM

Epirus Switzerland GmbH, a subsidiary of Boston-based Epirus Biopharmaceuticals, Inc., and Ranbaxy Laboratories Limited, a division of Daiichi Sankyo, announced the signing of a licensing agreement for BOW015, a biosimilar infliximab, for the broad range of territories including India, selected South East Asian markets, North Africa and several other markets.

Under the terms of the agreement Epirus and Ranbaxy will initially pursue the commercialization of BOW015, the EPIRUS biosimilar molecule to Remicade in India. Epirus recently announced successful Phase 3 data for BOW015 and, in November, filed for market approval.

Subsequent to launch in India, Ranbaxy will pursue registration and commercialization of BOW015 in other territories in South East Asia, North Africa and selected other markets.

In exchange for the rights to BOW015 in the territories, Epirus will receive upfront, milestone, and royalty payments over the term of the agreement.

“We are very pleased to work with Ranbaxy to register and commercialize this important medicine. Ranbaxy has the right focus and infrastructure in these markets to effectively bring this medicine to these markets”, said Amit Munshi, President and CEO of Epirus.

Arun Sawhney, CEO & Managing Director, Ranbaxy said, “We are excited to partner with Epirus for the supply of this important high-quality biosimilar medicine. We will utilise our strong front-end capabilities in making this product available in India and other parts of world.”


Source: Epirus Biopharmaceuticals press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!